Medically reviewed by Marla Anderson, MD HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is ...

The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...

为探究乳腺癌脑转移（BCBMs）治疗策略变化对患者结局的影响，意大利和法国多家机构研究人员开展相关研究。结果发现仅 HR-/HER2 + 患者总生存期改善。该研究对优化治疗、评估预后意义重大，值得科研读者一读。

The following is a summary of "HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials ...

Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative ...

点击蓝字关注我们【导读】这项III期试验旨在比较ARX788和拉帕替尼加卡培他滨治疗人表皮生长因子受体2（HER2）阳性晚期乳腺癌（ABC）患者的疗效。2025年2月17日，NovoCodex ...

为解决 ER+、HER2 阳性或阴性转移性乳腺癌中 FDG 和 FES-PET 成像效用不明的问题，华盛顿大学等研究人员开展相关研究，发现两者摄取相似，FES-PET 或可筛选患者。推荐阅读，了解乳腺癌诊疗新依据。

Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

2025 年 1 月 18 日，由北京市希思科临床肿瘤学研究基金会、杭州东方临床肿瘤研究中心共同主办的「2024 胃肠肿瘤年终大盘点」盛大召开。会议中揭榜 2024 胃肠领域十大临床热词，其中，肿瘤经典靶点人表皮生长因子受体 2（HER2）和抗 ...

Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatment technologies have opened new avenues for ...

A Stirling mother diagnosed with breast cancer at 33 is to take part in Breast Cancer Now’s Pink Ribbon Walk. Alex McSharry, ...